Table 1

Clinical characteristics of asthmatic patients











Treatment











Patient number
 Age (yr)
 Sex
 Height (cm)
 Type
 Severity
 Total IgE in serum (IU/ml)
 Specific IgE in serum
 Complication of allergic disease
 RT20-FEV1 (mg/ml)*
 Bronchodilator response (%)**
 BDP (μg/day)
 Theophylline (mg/day)
 Clenbuterol (μg/day)
 Carbocysteine (mg/day)
1
 81
 M
 154
 Int
 Moderate
 75
 -
 -
 2.50
 34.0
 800
 0
 40
 1500
2
 72
 F
 151
 Ext
 Moderate
 464
 HD
 AR
 2.50
 25.4
 800
 0
 0
 0
3
 80
 F
 143
 Ext
 Moderate
 3
 Mite, HD
 -
 1.25
 27.0
 800
 0
 40
 0
4
 72
 F
 148
 Int
 Mild
 28
 -
 -
 0.08
 19.4
 0
 0
 0
 1000
5
 79
 F
 142
 Int
 Moderate
 37
 -
 -
 5.00
 27.6
 800
 0
 20
 1500
6
 72
 F
 150
 Int
 Moderate
 57
 -
 -
 0.31
 22.3
 400
 0
 40
 0
7
 72
 F
 147
 Ext
 Moderate
 647
 HD, Ceder
 -
 0.31
 31.8
 800
 0
 20
 1500
8
 70
 F
 140
 Int
 Moderate
 17
 -
 -
 1.25
 17.6
 800
 0
 40
 1500
9
 75
 M
 162
 Ext
 Moderate
 148
 HD, Ceder
 AR
 2.50
 14.1
 800
 0
 40
 1500
10
 71
 M
 165
 Ext
 Moderate
 133
 Mite, Ceder
 AR
 1.25
 14.6
 0
 0
 40
 1500
11
 80
 M
 165
 Int
 Moderate
 2
 -
 -
 2.50
 12.6
 400
 0
 0
 0

Ext, extrinsic; Int, intrinsic; HD, house dust; AR, allergic rhinitis; BDP, beclomethasone diproprionate inhalation.

*PC20-FEV1 shows concentration of inhaled methacholine causing a 20% fall in FEV1.

**Bronchodilator response means percent increase in forced expiratory volume in 1s (FEV1) from the baseline value after inhalation of 300 μg of salbutamol sulfate.

All patients used inhaled β2-agonists (salbutamol or procaterol) on demand.

Ishiura et al. Cough 2005 1:11   doi:10.1186/1745-9974-1-11